Lumen - Biologic Drug for C. difficile Colitis

Traditionally considered a hospital-acquired infection, C. difficile is  increasingly arising in the broader community. For this reason, the shelf-stable, orally delivered format of Lumen’s product is an important addition to the tool kit for treating and preventing this disease. Long-term consequences can include chronic diarrhea, severe intestinal inflammation, surgical resection, and death. Insidiously, the very thing that is used to treat this infection—broad spectrum antibiotics—is also the thing that causes the disease. C. difficile therefore appears at the top of the CDC’s antimicrobial threats list year after year, and in 2009 was estimated to single-handedly drive 2.3% of all US hospital costs.